Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Nilanjan Choudhury headshot

4 Top-Ranked Energy Stocks to Scoop Up Post Monday's Rally

DCP Midstream (DCP), Abraxas Petroleum (AXAS), Matador Resources (MTDR) and NuStar (NS) were up more than 10% yesterday with more gains ahead on a potential coronavirus treatment and revival in oil demand.

Nalak Das headshot

5 Blue-Chip Stocks to Buy on Coronavirus Vaccine Hope

A COVID-19 vaccine likely to benefit the Dow the most as it is more inclined toward cyclical stocks. Five among these are NIKE (NKE), Dow (DOW), The Procter & Gamble (PG), 3M (MMM) and Microsoft (MSFT).

Sanghamitra Saha headshot

5 ETFs Up Double Digits in a Day on Vaccine Optimism

Wall Street soared on Nov 9 on news that Pfizer (PFE) and BioNTech (BNTX) vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial.

Tirthankar Chakraborty headshot

2 Stocks to Watch on Pfizer's 90% Effective COVID-19 Vaccine

Pfizer's (PFE) shares hit an all-time high during yesterday's trading session on its milestone COVID-19 vaccine news, while Moderna's (MRNA) soared on optimism as it applies a similar technology.

Daniel Laboe headshot

More Foot-Traffic & Less Click-Traffic

Yesterday's hopeful vaccine news from Pfizer (PFE) and BioNTech (BNTX) has put a light at the end of the tunnel for value investors

Daniel Laboe headshot

More Foot-Traffic, Less Click-Traffic Pt. 2

It's day 2 of the market rotation out of secular growth and into beaten-down value names reversing 2020???s digitally-driven equity trend

Mark Vickery headshot

Markets Rejoice Pfizer (PFE) Vaccine News

For the month of November thus far, the Dow has already climbed more than 10%.

Benjamin Rains headshot

3 Highly-Ranked Large Cap Stocks to Buy Now

We explore three large-cap Zacks Rank #1 (Strong Buy) stocks that investors might want to buy right now that don't have to count on Pfizer's (PFE) vaccine progress...

John Blank headshot

The Sea Looks Calm: Global Week Ahead

This is not going to be an interesting week, relative to last week's exhausting line-up of major events. ??????That's OK with me. I expect it is OK with you, too.

Positive News on COVID-19 Vaccine

Positive News on COVID-19 Vaccine

Mark Vickery headshot

Pfizer's Covid Drug Proves 90%+ Effective; PFE, BNTX

A Covid vaccine takes the lid off most everything market-related. That said, we're still looking at a period of months before it would be widely available.

Daniel Laboe headshot

What A Vaccine Means For The Stock Market

The markets are pricing in the end of the pandemic. This means more foot traffic and less click traffic.

Aerie (AERI) Q3 Loss Narrower Than Expected, Sales Rise Y/Y

Aerie (AERI) reports a narrower-than-expected loss and revenues beat estimates in the third quarter of 2020.

Mylan's (MYL) Q3 Earnings Surpass Estimates, Sales Miss

Mylan (MYL) beats on Q3 earnings but misses on sales. The company is all set to merge with Pfizer's Upjohn business later in the month.

Bristol-Myers (BMY) Q3 Earnings Beat, '20 EPS View Raised

Bristol-Myers (BMY) beats on earnings and sales in the third quarter on strength of Revlimid and Eliquis.

Ionis (IONS) Misses Estimates for Q3 Earnings and Sales

Ionis (IONS) posts wider-than-expected Q3 loss. Sales miss estimates.

AstraZeneca (AZN) Q3 Earnings Miss Estimates, Sales Beat

AstraZeneca (AZN) lags Q3 earnings estimates and surpasses the same for sales. It maintains its financial outlook for the year.

Can Coronavirus Vaccine Efforts Aid BioNTech (BNTX) Q3 Earnings?

On BioNTech's (BNTX) upcoming Q3 earnings call, investors' focus will be on the progress and advancement of its COVID-19 vaccine candidate, currently being developed in partnership with Pfizer.

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J

Mylan (MYL) to Report Q3 Earnings: Is a Beat in the Cards?

Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q3 results.

Kinjel Shah headshot

Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study

Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Novartis (NVS) and others release Q3 results

The Zacks Analyst Blog Highlights: UnitedHealth Group, Adobe, Pfizer, Intel and T-Mobile US

The Zacks Analyst Blog Highlights: UnitedHealth Group, Adobe, Pfizer, Intel and T-Mobile US

Glaxo (GSK) Q3 Earnings Top, Vaccines Segment on Recovery Path

Glaxo (GSK) witnesses recovery in vaccinations rates in the third quarter. Performance of Pharmaceuticals and Consumer Healthcare businesses improve.

Sheraz Mian headshot

Top Research Reports for UnitedHealth, Adobe & Pfizer

Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group (UNH), Adobe (ADBE) and Pfizer (PFE).

John Blank headshot

Update on the COVID Vaccine Race

A 2021 Macro Recovery is About This, Alone.